The adhesive protein, von Willebrand factor (VWF), mediates the initiation and progression of thrombus formation at sites of vascular injury by means of specific interactions with extracellular matrix components and platelet receptors. The essential biologic properties of VWF have been elucidated, with progress particularly in the areas of genetic regulation, biosynthesis, and specific bimolecular interactions. The threedimensional structure of selected domains has been solved, but our understanding of detailed structure-function relationships is still fragmented, partly because of the complexity and size of the VWF molecule. The biomechanical properties of the interaction between the VWF A1 domain and the platelet receptor glycoprotein (GP) Ib␣ also are better known, but we can still only hypothesize how this adhesive bond can oppose the fluid dynamic effects of rapidly flowing blood to initiate thrombus formation and contribute to platelet activation. Elucidating the details of VWF and GPIb␣ function will lead to a more satisfactory definition of the role of platelets in atherothrombosis, since hemodynamic forces greatly influence responses to vascular injury in stenosed and partially occluded arteries. Progress in this direction is also aided by rapidly expanding novel information on the mechanisms that regulate VWF multimer size in the circulation, a topic of relevance to explain microvascular thrombosis and, perhaps, arterial thrombosis in general. Developments in these areas of research will refine our understanding of the role played by VWF in vascular biology and pathology. Semin Hematol 42:5-14
T he response of platelets to vascular injury involves multiple vessel wall structures as well as cellular and soluble blood components. Among these, von Willebrand factor (VWF) and one of its platelet receptors, the glycoprotein (GP)Ib␣ in the GPIb-IX-V membrane complex, 1 can mediate platelet adhesion to extracellular matrices and to one another, opposing high shear stress, a hemodynamic condition present in areas of rapid blood flow such as microarterioles or stenosed arteries. This distinctive property makes VWF and GPIb␣ uniquely important for normal hemostasis and, presumably, central players in arterial thrombosis. 2 VWF also associates with the procoagulant factor VIII (FVIII), forming a complex that regulates FVIII secretion inside cells 3 and prevents its rapid clearance in the circulation. 4 The congenital deficiency of VWF function results in a bleeding tendency known as von Willebrand disease, 5 which occasionally may present as an acquired condition. 6 Comprehensive reviews on VWF have been published 7, 8 ; here, after a description of general concepts, attention will be focused on the structural and functional properties that characterize this unique prothrombotic molecule.
Biosynthesis and Structure of von Willebrand Factor
Mature VWF is a multimeric protein; molecules are composed of a variable number of identical subunits, each comprising 2,050 amino acid residues and up to 22 carbohydrate side chains. 9 Subunits are disulfide-bonded into dimers of approximately 500 kd, which in turn are disulfide-linked into multimers of increasing size that may exceed 10,000 kd. The largest VWF molecules have been visualized by electron microscopy as elongated or coiled filaments with lengths up to 1,300 nm (about the diameter of a platelet) or cross sections of 200 to 300 nm, respectively. 10 The size and shape of VWF molecules may influence their function, as discussed below.
Biosynthesis and Secretion of von Willebrand Factor
The large VWF gene (180 kb) is located on the short arm of chromosome 12 and contains 52 exons. Expression is restricted to endothelial cells and megakaryocytes. The primary mRNA translation product, pre-pro-VWF, is a 2,813-residue polypeptide consisting of a 22-residue signal peptide, a 741-residue propeptide, and the 2,050-residue mature subunit. The propeptide and mature subunit constitute pro-VWF, composed of four types of repeating domains in the order D1-D2-D=-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2 from amino (NH 2 )-to carboxyl (COOH)-terminal end.
After removal of the signal peptide from pre-pro-VWF and completion of the initial glycosylation, 11 pro-VWF monomers associate into dimers through intermolecular disulfide bridges within their COOH-terminal regions (residues 1,908 to 2,050). 12 Further processing of pro-VWF dimers is then followed by the noncovalent association of propeptide regions that promotes the assembly of larger multimers linked through disulfide bridges in the NH 2 -terminal D3 domain. This step depends on the function of vicinal cysteine residues with endogenous disulfide isomerase-like activity 13 and is followed by the targeting of VWF multimers to storage granules. 14 In endothelial cells, VWF is stored in Weibel-Palade bodies that form only after VWF is synthesized but regardless of multimer assembly 15 ; in megakaryocytes and platelets, VWF is stored in ␣-granules, 16 whose presence does not depend on VWF synthesis. The noncovalent propeptide dimer is removed by specific proteolysis before secretion and independently released into circulating blood, where it was originally identified as von Willebrand antigen II (VWAgII). 17 Two pathways of secretion, a constitutive one coupled to synthesis and a regulated one involving storage and release by secretagogues, 11 direct the release of endothelial cell-derived VWF both towards the lumen and the extracellular matrix. This polarity may be influenced by the nature of the release-inducing stimulus. In megakaryocytes and platelets only the regulated pathway is effectively operative in vivo; thus, the all of the VWF circulating in plasma is essentially of endothelial cell origin. 18 
Structure of von Willebrand Factor Functional Domains
Discrete domains within the VWF subunit exhibit specific functions, and several have been expressed as active fragments independently of multimer assembly. The recognized functional domains are D=, with a binding site for factor VIII and one for heparin; A1, with the binding site for platelet GPIb␣ as well as additional sites for collagens, heparin, sulfated glycolipids, and heterologous molecules such as the snake protein, botrocetin; A3, with an important binding site for collagens; and C1, with the integrin recognition sequence, Arg-Gly-Asp. Domain A2 does not contain a direct functional site but is important as the target of the metalloproteinase, ADAMTS13, 19, 20 which cleaves specifically the Tyr842-Met843 peptide bond. 21 (Numbering is based on the mature subunit sequence beginning with Ser1, which is Ser764 of pre-pro-VWF where residue 1 is the initiating Met; thus, residues in the mature VWF subunit correspond to those in pre-pro-VWF after adding 763.) This cleavage has effects on the size of circulating multimers 22 and consequently modulates proadhesive functions (see below). Particular attention has been devoted to the VWF domains that promote platelet adhesion to extracellular matrix components, namely, A1 and A3, for which atomic structures have been obtained.
Structure of the VWF A1 Domain
The A1 domain, which contains the only known binding site for GPIb␣, has a typical ␣/␤ fold with six hydrophobic parallel ␤ strands forming a central ␤-sheet flanked by six ␣-helices, three on each side. 23 If one considers the A1 domain as a cube oriented such that the bottom face contains the intrachain disulfide bond formed by Cys509 and Cys695, then positively and negatively charged residues are clustered on the opposite right and left faces, respectively. Residues on either side of the disulfide bond are packed against the bottom face of the domain by hydrophobic or salt-bridge interactions. The structural bases of VWF A1-GPIb␣ binding have been elucidated by the crystallization of two complexes, the first containing gain-offunction mutations in both A1 domain (Arg543Gln) and GPIb␣ amino terminal domain (Met239Val), 24 and the more recent one obtained with wild-type molecules. 25 The difference in binding affinity between the two complexes is approximately 2.5-fold. Both structures indicate that the GPIb␣ binding surface is discontinuous and involves two areas: the larger one, located on the upper-front face of the A1 domain, includes helix ␣3, loop ␣3-␤4, and strand ␤3; the smaller one, located on the bottom face, includes loops ␣1-␤2, ␤3-␣2, and ␣3-␤4. The two crystal structures differ substantially in the position of the ␣1-␤2 loop of the VWF A1 domain, a difference that is not observed in the uncomplexed native and mutant molecules but only upon their binding to GPIb␣. 25 In the bound mutant A1 domain, the ␣1-␤2 loop has a more extended conformation and protrudes towards the interior of the GPIb␣ binding pocket, which may lead to more electrostatic interactions between receptor and ligand and therefore a tighter bond. In contrast, in the bound wild-type A1 domain, the loop has a more open conformation and is not as close to GPIb␣ residues as the corresponding loop in the mutant A1 domain, such that several water molecules are incorporated at the contact interface. 25 Different crystal structures of uncomplexed A1 domain have revealed several conformations that appear to be intermediate between the open one of the bound wild-type and the extended/closed one of the bound Arg543Gln mutant. This suggests that conformational adaptations of the ␣1-␤2 loop may be responsible for affinity modulation of VWF A1-GPIb␣ binding.
Functional Modulation of the VWF A1 Domain
Native VWF in solution has no measurable affinity for GPIb␣, a condition that is thought to prevent binding to platelets in circulating blood. Mechanisms exist that promote the interaction at sites of vascular injury in order to initiate thrombus formation. As described above, one such mechanism may involve conformational changes in the ␣1-␤2 loop located at the bottom face of the A1 domain. In this region of the molecule, residues on the NH 2 -and COOH-terminal sides of the Cys509-Cys695 disulfide bond may mask an area that contributes to the interaction with the GPIb␣. In native VWF, therefore, neighboring domains may impede A1 binding to platelets until the functional site is exposed through conformational rearrangements. In this regard, most gain-offunction mutations identified in type 2B von Willebrand disease 26 are clustered at the bottom face of the A1 domain. Mutations in this region may disrupt the salt-bridge or hydrophobic interactions that contribute to maintaining a nonfunctional closed conformation, thus enhancing GPIb␣ binding. In the case of the Ile546Val type 2B mutation, the crystal structure reveals structural changes propagated at a distance of 27 Å from the ␣1-␤2 loop, where the amino acid substitution occurs, and reflected mainly in reorientation of residues Asp560 and Gly561 that are part of the upper-front GPIb␣-binding surface. 27 The extent to which such changes contribute to the gain of function is still unclear, but the effects of these mutations are compatible with the concept that GPIb␣ binding involves an extended surface of VWF A1. Moreover, at least one type 2B mutation, Arg543Gln, resulted in structural alterations that became more apparent upon binding to GPIb␣, 25 highlighting the adaptive and dynamic nature of the interaction. In pathophysiologic situations, the two relevant conditions that may influence the VWF A1-GPIb␣ binding affinity, often acting in concert, are immobilization on a substrate and elevated fluid shear stress. 28 Both may contribute to the exposure of functional sites, as suggested by the occurrence of molecular shape changes induced by fluid dynamic forces in surface bound VWF. 29 Perhaps less relevant for a direct understanding of the physiologic modulation of A1 domain function is the information provided by the use of heterologous modulators such as ristocetin 30 and botrocetin, 31 a bacterial glycopeptide and snake protein, respectively. Both bind to the A1 domain: botrocetin to positively charged residues located on the righthand face of the molecule, 32 and ristocetin likely to a sequence including three consecutive proline residues (702 to 704) that flank Cys695 on the COOH-terminal side. 33 There is no evidence to date that these modulators act in a manner that reflects mechanisms relevant for biologic functions; yet, it must be noted that ristocetin-induced VWF-platelet interactions rather faithfully reflect the dysfunction caused by VWF mutations in normal hemostasis.
Structure of the VWF A3 Domain in Relation to Collagen Binding
There is general agreement that the VWF A3 domain contains a binding site for fibril-forming collagens (types I and III), whereas there is more controversial evidence on the contribution provided to collagen binding by the A1 domain. 7 The latter may be particularly important for binding to collagen type VI34, which is an important component of the subendothelial matrix. Fluid dynamic conditions and mechanical forces may modulate VWF-collagen interactions, and domains A1 and A3 may variably contribute to the immobilization of VWF onto extracellular matrices. This concept may explain the discrepant observations that an anti-VWF A3 domain antibody blocking binding to collagen had antithrombotic effects, 35 unlike mutations such as Ser968Thr that markedly inhibited the same interaction in vitro but had limited effects in vivo. 36 Thus, the immobilization of VWF onto extracellular surfaces mediated by the A3 domain may be variably relevant depending on the nature of the vascular lesion.
Determination of the crystal structure of the A3 domain has revealed a folding similar to that of the A1 domain. 37, 38 The putative location of collagen-binding residues was deduced from the structure of the A3 domain in complex with a function-blocking monoclonal Fab capable of inhibiting collagen binding. 39 The functional site may be located at the bottom face of the molecule, although mutagenesis studies have also indicated a role for residues on the front face. 40 Experiments with transferred cross-saturation, a technique based on nuclear magnetic resonance that allows the visualization of contact residues in large complexes, identified the front face of the A3 domain as the site for collagen binding. 41 This function of VWF A3 appears to be constitutively expressed and independent of specific conformational changes, although it may involve an induced-fit mechanism. 39 
Functions of von Willebrand Factor in Platelet Adhesion and Aggregation

Platelet Thrombus Formation in Flowing Blood
The complex interactions that involve cells, the vessel wall and molecules in solution during a normal hemostatic response are influenced by the flow of blood. The velocity of blood near the wall is lower than at the center of the vessel, and this difference creates a shearing effect between adjacent layers of fluid that is greatest at the luminal surface, decreasing progressively towards the center of the vessel (Fig 1) . Shear rate, a difference in flow velocity as a function of distance from the wall, is expressed in cm/s per cm or the equivalent inverse seconds (s Ϫ1 ). Fluid shear stress is a force per unit area and is expressed in Pascal (Pa), equivalent to 1 N/m 2 or in dynes/cm 2 (1 Pa ϭ 10 dynes/cm 2 ). The shear rate is directly proportional to the shear stress and inversely proportional to the fluid viscosity. In blood, where viscosity is approximately 0.004 Pa · s (or 0.04 dynes/cm 2 · s), a shear stress of 1 dyne/cm 2 corresponds to a shear rate of 25 s Ϫ1 . The force (drag) that opposes stable platelet adhesion and aggregation increases with the shear rate. Consequently, shear-depen-dent phenomena are more relevant in those districts of the vasculature where shear forces are greater (that is, in arteries more than in veins) and, particularly, in arterioles. The highest wall shear rate in the normal circulation occurs in small arterioles of 10 to 50 m diameter where levels have been estimated to vary between 500 and 5,000 s Ϫ1 . Wall shear rates of 3,000 to 10,000 s Ϫ1 have been measured at the top of plaques causing 50% occlusion of coronary arteries, 42 and values in excess of 50,000 s Ϫ1 have been estimated to occur at the apex of a more severe stenosis. 43, 44 Thus, shear stress is of greater pathogenic relevance in conditions predisposing to acute arterial occlusion than it is in the course of normal hemostasis.
Regulation of VWF Multimer Size in the Circulation and Its Relationship to Thrombogenesis
The largest VWF multimers display enhanced thrombogenic functions, possibly because multiple interactive sites for vessel wall components and platelets support more efficient adhesion. The most active multimers are normally present in storage granules within cells and are not seen in blood, where they can be detected as unusually large multimers only transiently after induction of secretion from endothelial storage sites. 45 The controlled release of the largest VWF multimers at the time of injury limits their presence at sites of tissue damage, and physiologic regulatory mechanisms cause their disappearance from the circulation, possibly to prevent excessive thrombus formation. The main mechanism regulating plasma VWF size involves specific proteolysis by ADAMTS13. 46, 47 Mutations of ADAMTS13 have been identified in patients with chronic relapsing thrombocytopenic purpura, 46 a discovery that correlates the altered processing of VWF multimers in blood to the microvascular thrombotic complications typical of this disorder. 48 Deficiency of ADAMTS13 activity has also been correlated to enhanced shear-induced platelet aggregation, 49 which may explain the preferential onset of thrombosis in small arterioles where shear stress is elevated. ADAMTS13 can cleave newly secreted ultralarge VWF multimers on the surface of endothelial cells, 50 and a defect in this function may influence the local progression of prothrombotic events. 51 There is an obvious interest in determining whether a similar mechanism might contribute to precipitating acute thrombotic complications of coronary artery and cerebrovascular disease, and more studies will undoubtedly be devoted to address this question. In addition to proteolysis, the regulation of VWF multimer size may depend on a disulfide bond reductase activity ascribed to thrombospondin-1. In this process, disulfide bonds linking VWF subunits are rearranged such that the largest multimers are "depolymerized," reversing the assembly achieved during biosynthesis. 52 
Initial Platelet Attachment to Thrombogenic Surfaces
Distinct ligand-receptor interactions initiate thrombogenesis at sites of vascular injury depending on the velocity of flowing blood. Above a limiting shear rate (ϳ1,000 s Ϫ1 ) the process is absolutely dependent on VWF and its GPIb␣ receptor, even on substrates such as collagen and complex extracellular matrices that are intrinsically capable of initiating adhesion at lower shear rates 53 (Fig 2) . The distinguishing feature of the VWF A1 domain-GPIb␣ interaction is the ability to support platelet tethering to thrombogenic surfaces even when the velocity of flowing blood relative to the vessel wall is elevated. However, the interaction is also characterized by a fast dissociation rate and cannot support irreversible adhesion, 54 so that platelets tethered in such a manner to the vessel wall move constantly in the direction of flow (Fig 2) . The translocation velocity is typically less than 2% of the free flow velocity of noninteracting platelets at the same distance from the luminal surface. This slow motion allows the establishment of additional bonds through receptors that belong mostly, but not necessarily, to the integrin superfamily. Such receptors typically have a slower rate of bond formation as compared to GPIb but are capable of mediating stable interactions that lead to the definitive arrest of individual platelets and subsequent thrombus development. Notable in this regard is the role of the activated integrin ␣IIb␤3, which can bind to the Arg-Gly-Asp sequence in VWF itself 55, 56 or to other adhesive substrates in a complex matrix, and of collagen and its receptors. 53, 57, 58 When VWF is bound to collagen, Figure 1 Normal endothelial cells are nonreactive for platelets, but exposed subendothelial structures induce rapid platelet adhesion. Hemodynamic forces influence these events in flowing blood. Blood flow in a cylindrical vessel can be visualized as a series of fluid layers (laminae) moving at different velocity. The laminae near the center of the vessel have greater velocity than those near the wall (depicted schematically by arrows of different length). The corresponding velocity profile (solid line) is more blunted than the parabolic profile expected with a homogeneous suspension (dotted line) owing to cell depletion in the boundary layer near the wall. The shear rate is the rate of change of velocity with respect to distance measured perpendicularly to the direction of flow. The negative sign indicates that the gradient is defined from the center (where velocity is maximal) to the wall (where velocity is minimal).
Figure 2
Schematic representation of the sequential process of platelet adhesion and thrombus formation onto collagen type I fibrils under a high shear rate. (a) VWF bound to collagen is required to establish the first contact between platelets and the surface when the shear rate exceeds a threshold value (ϳ1,000 s Ϫ1 with human blood). The VWF A1-GPIb␣ bonds forms rapidly and have high resistance to tensile stress but an intrinsically limited half-life. In the absence of other bonds, platelets detach at the tailing edge where tension is greatest and move forward with a rotational movement (rolling) due to the torque imposed by the flowing fluid. New VWF A1-GPIb␣ bonds form as different regions of the membrane of rolling platelets come close to the surface, thus platelets remain in contact with the substrate for extended periods of time while translocating at low velocity. In normal conditions, however, the initial tethering to VWF is rapidly followed by binding to collagen through specific receptors (namely, GPVI and ␣ 2 ␤ 1 ), followed by firm adhesion, activation, and additional stable bonds mediated by ␣ IIb ␤ 3 . (b) The first layer of activated platelets firmly attached to a reactive surface becomes the substrate for accumulation of more platelets and thrombus growth. Adhesive ligands, mainly fibrinogen and VWF, bind to activated ␣ IIb ␤ 3 on the membrane of the adherent platelets and become the substrate for the attachment of incoming platelets. The unique biomechanical properties of the VWF A1-GPIb␣ bond are required for the initial tethering of flowing platelets to adherent platelets when the shear rate is elevated. This explains why in rapidly flowing blood VWF and GPIb␣ play a key role both during initial platelet adhesion and subsequent aggregation. (c) Visualization of platelet rolling on immobilized VWF by time-lapse videomicroscopy. Blood containing as anticoagulant the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone dihydrochloride (PPACK; 40 mol/L final concentration) as well as prostaglandin E 1 to inhibit platelet activation was perfused through a parallel plate flow chamber at 37°C with a wall shear rate of 1,500 s Ϫ1 . Platelets were rendered fluorescent by the incorporation of mepacrine. The image on the left is a single frame showing a snapshot of individual platelets interacting with the VWF-coated surface. The image on the right shows the superimposition of 30 consecutive frames captured a sampling rate of three frames per second. The occurrence of platelet translocation on VWF is rendered by the streaking effect produced by moving platelets. (d) VWF is required for thrombus formation on collagen when the shear rate is high but not when it is low. The two images on the left show the thrombi formed when control blood was perfused over collagen type I fibrils at two different shear rates. The two images on the right show the thrombi formed when the same blood was treated before perfusion with an anti-VWF A3 antibody that blocks binding to collagen. Thrombus formation was abolished when the shear rate was 1,500 s Ϫ1 but minimally affected when the shear rate was 500 s Ϫ1 . the transition from rolling to stable adhesion occurs much more rapidly than on immobilized VWF alone, indicating the effect of multiple activating signals.
An additional mechanism has been elucidated that highlights how soluble plasma VWF may contribute to platelet adhesion. 59 A process of self-association occurs at the interface between soluble and surface-bound VWF, such that the first layer of VWF multimers bound to matrix collagen supports the transient adsorption of additional multimers from plasma to which platelets can readily attach. This mechanism was demonstrated by binding to collagen a mutant VWF devoid of domain A1, thus unable to promote platelet adhesion, and showing that GPIb␣-mediated tethering was restored by the presence of soluble VWF in plasma (Fig 3) . The adsorption of soluble VWF to immobilized VWF is a reversible process since the number of platelets-surface contacts on immobilized ⌬A1-VWF is rapidly reduced when the pefusing blood is replaced with a plasma-free blood suspension. 59 Plasma VWF, therefore, has a dual role in mediating platelet adhesion under flow: one involves the A3 domain through which tight binding to collagen is established, and the other is a reversible self-association with immobilized VWF that can modulate and reinforce the adhesive properties of the latter. These findings demonstrate that a direct linkage between VWF and a surface such as collagen is not an absolute requisite for the expression of GPIb␣ binding function.
The VWF-GPIb␣ Interaction in Arterial Disease
In diseased arteries, the tethering of flowing platelets to exposed VWF may precipitate the thrombotic occlusion of the vessel lumen with obstruction to blood flow and subsequent tissue damage. 2 Shear stress is particularly elevated around Figure 3 Role of soluble VWF A1 domain in mediating platelet interaction with surface-bound VWF. A washed blood cell suspensions devoid of plasma proteins and containing EDTA, to block integrin function in adhesion and aggregation, and prostaglandin E 1 , to block platelet activation, was perfused over immobilized collagen type I fibrils at the wall shear rate of 1,500 s Ϫ1 . (a) Control experiment with normal multimeric VWF added to the cell suspension. The A3 domain mediates VWF binding to collagen, and the A1 domain interacts with platelet GPIb␣; tethered platelets are seen rolling on the surface, which is represented by an electron micrograph of collagen fibrils. (b) Experiments performed after adding to the cell suspension recombinant VWF devoid of the A3 domain (⌬A3-VWF), which cannot bind to collagen; or (c) recombinant VWF devoid of the A1 domain (⌬A1-VWF), which binds to collagen but cannot interact with platelet GPIb␣. In either case, no platelets are seen tethered to the surface. (d) The collagen fibrils were precoated with ⌬A1-VWF multimers, which cannot initiate platelet tethering, and then exposed to the blood cell suspension containing ⌬A3-VWF. Although the latter cannot bind directly to collagen (see b), it could compensate for the lack of A1 domain in the surface-bound VWF and restore platelet tethering. The association of VWF multimers with one another can explain this result; the two-sided arrows between multimers indicate that the association is reversible. The images are single frames from a real time recording representing an area of 65,536 m 2 . The bar graph shows the number of platelets tethered to the surface under the different experimental conditions described above (mean Ϯ SEM of two separate experiments). Adapted from Savage et al 59 and reprinted with permission. atherosclerotic lesions because lumen restriction causes a local increase in blood flow velocity. High shear stress may specifically enhance platelet reactivity through the VWFGPIb-IX-V pathway of platelet adhesion and activation. 60, 61 Clinical and experimental evidence may link VWF to acute arterial thrombosis. For example, diabetes is an established risk factor for cardiac death, and increased levels of VWF are significantly and independently associated with diabetes in patients who have suffered a myocardial infarction. 62 Moreover, VWF-mediated platelet adhesion to the vessel wall may also contribute to the genesis and progression of atherosclerotic plaques, which represent the chronic vascular alteration onto which acute arterial thrombosis develops. In this regard, enhanced secretion of VWF in response to inflammatory stimuli can lead to the local recruitment of platelets, and the process may be favored by hypercholesterolemia. 63 This may be one of the reasons why deficiency of VWF affords some level of protection from atherosclerosis. 64 
VWF-Mediated Signaling Through GPIb␣ and Platelet Activation
The binding of the VWF A1 domain to GPIb␣ elicits signals-including elevation of cytosolic Ca 2ϩ and activation of protein kinase C and tyrosine kinases-that may contribute to platelet activation. These signals can be detected under static conditions, 65,66 but they may be particularly relevant for the activation of platelets exposed to high shear stress. 67 Two distinct elevations of intracytoplasmic Ca 2ϩ have been documented in association with platelet GPIb␣-mediated adhesion to immobilized VWF (Fig 4) . A first rise in [Ca 2ϩ ] i , designated an ␣/␤ peak, occurs during the initial contacts that are still potentially reversible and always precedes stable platelet attachment. Type ␣/␤ peaks involve Ca 2ϩ release from intracellular stores. A second Ca 2ϩ signal, designated a ␥ peak, occurs in platelets that have established firm adhesion through the integrin ␣IIb␤3 and appears to be required for subsequent aggregation. Type ␥ peaks involve a transmembrane Ca 2ϩ flux. Thus, the initial GPIb␣ interaction with the VWF A1 domain leads to first-level ␣IIb␤3 activation sufficient for stable platelet adhesion to immobilized VWF but not for binding soluble VWF or fibrinogen (required for aggregation). Progression to thrombus formation requires further ␣IIb␤3 activation that is contingent on signal amplification associated with type ␥ [Ca 2ϩ ] i peaks (Fig 4) . Inhibition of phophatidylinositol 3 kinase (PI3-K) activity or removal of adenosine triphosphate (ADP) with apyrase blocks ␥ peaks and prevents platelet aggregation. 67, 68 While apyrase has no effect on the frequency or amplitude of ␣/␤ peaks, the use of specific inhibitors highlights an important role of the P2Y 1 ADP receptor in reinforcing the initial signal induced by GPIb␣ binding to VWF A1. Thus, the latter interaction causes ADP release that acts rapidly through P2Y 1 in enhancing Ca 2ϩ release from intracellular stores, such that enzymatic degradation of ADP by apyrase is not sufficiently rapid to block this activity. 69 In contrast, a subsequent effect of ADP required for platelet aggregation and mediated by a different receptor, P2Y 12 , can be blocked efficiently by apyrase. 69 Signaling dependent on the VWF A1 domain is thought to involve the cross-linking (receptor clustering) of GPIb␣ subunits by multivalent VWF. 65 The observation that a subpopulation of platelet GPIb-IX-V is associated with FcR␥-chain, which contains an ITAM (immuno-receptor tyrosine-based activation motif) module, lends support to the cross-linking mechanism of signaling. 70 -72 FcR␥-chain and GPIb␣ are proximal to within 10 nm of each other in the platelet membrane. 73 Nevertheless, VWF A1 domain-induced signaling through GPIb␣ can activate ␣IIb␤3 in a manner that is independent of other receptors. 66 In particular, mouse platelets expressing human GPIb␣ but lacking the FcR␥-chain adhere to a dimeric VWF A1 domain and undergo Ca 2ϩ oscillations in a manner that is qualitatively similar, albeit slightly impaired, to that seen with mouse platelets expressing both receptors. Thus, the FcR␥-chain contributes to maximal Ca 2ϩ elevations, but it is not strictly required for the initiation of Ca 2ϩ responses.
Thrombus Propagation Under Flow
The response of platelets to vascular injury involves a series of coordinated reactions initiated by tethering to appropriate substrates linked to activation processes that promote the binding of soluble adhesive proteins and the recruitment of additional platelets. The time course of this sequence of events is influenced by the composition of the reactive surface exposed to flowing blood. In the setting of vascular lesions, subendothelial components such as collagen and soluble platelet agonists such as ADP, epinephrine, and ␣-thrombin may greatly enhance the efficiency of the hemostatic response by contributing synergistically to ␣IIb␤3 activation. It is apparent that soluble agonists may influence thrombus formation at sites of injury, but in the early stages of the process a relevant role is likely played by activation signals originating from the engagement of adhesion receptors. Indeed, irreversible platelet adhesion to matrices containing collagen type I is essentially instantaneous even at the highest levels of shear stress, and thrombus formation ensues within seconds. 53 After platelets adhere to a vascular lesion and become activated, thrombus growth proceeds through local accumulation of additional platelets in a process of homotypic aggregation. During this phase, activated adherent platelets bind soluble adhesive proteins, mainly fibrinogen and VWF, which upon immobilization onto the cellular membrane become substrates for the adhesion of circulating platelets in successive layers. 53 VWF released from activated platelets may play a role at this stage by increasing the local ligand concentration and membrane binding. Activation of the newly recruited platelets continues the process until the thrombus mass grows sufficiently to arrest blood loss from an injured vessel or, in pathologic conditions, until regulatory mechanisms interrupt the cycle or the vascular lumen is occluded. Thus, notwithstanding the importance of initiating events, a thrombus is constituted essentially of platelets linked to one another but not directly to subendothelial components, and its development is strictly dependent on the formation of interplatelet bonds.
Fibrinogen bound to activated ␣IIb␤3 is generally considered the predominant adhesive bridge between aggregating platelets. 74 At elevated shear rates, typically in excess of 5,000 s Ϫ1 , VWF can also bind to platelets in a process that involves sequentially GPIb␣ and ␣IIb␤3 and is thought to mediate aggregation in alternative to fibrinogen. 28, 75 Such concepts, however, have been suggested by the results of experiments with platelets in suspension not interacting with a reactive substrate. Studies on the bonds that link platelets to one another during thrombus development on collagen type I fibrils indicate a synergistic role for fibrinogen and VWF in supporting platelet aggregation. In the absence of fibrinogen, VWF-mediated thrombi grow rapidly at high shear rates but are unstable; in the presence of VWF and fibrinogen, thrombi grow more slowly, but are stable. 61 Unstable thrombi in the absence of fibrinogen have also been seen in the mouse circulation. 76 These results provide a plausible explanation for the altered hemostatic properties of platelets from patients with isolated congenital deficiency of either fibrinogen or VWF. Because neither protein by itself can sustain the full development of stable thrombi within the range of pathophysiologically relevant flow conditions, hemostasis cannot be normal unless both are present and functional. Studies in genetically modified mice have indicated that thrombus formation may persist even in the absence of both fibrinogen and VWF, 77 and evidence has been obtained that fibronectin, another ligand for activated ␣IIb␤3, may contribute to platelet aggregation within a thrombus. 78 In this regard, therefore, it appears that several ␣IIb␤3 ligands support thrombus stability, including CD40 ligand. 79 The role of different adhesion receptors in mediating interplatelet contact has been analyzed with two-step perfusion experiments. 61 These studies have shown that thrombus height is limited by the inhibition of GPIb␣ even when blood is initially perfused at shear rates permissive of adhesion to collagen without participation of the GPIb␣-VWF interaction. This is because the shear rate increases at the apex of a growing thrombus where the flow channel narrows, such that the threshold may be reached at which only a rapidly forming bond can capture flowing platelet. Thus, the synergy between fibrinogen and VWF in supporting platelet aggregation depends on the recognized ability of each of these molecules to establish bonds with distinct adhesive properties.
Conclusions
Progress in understanding the structure and function of VWF and the mechanisms that underlie its interactions with vascular surfaces and platelets can elucidate important aspects of normal hemostasis and pathologic arterial thrombosis. This knowledge may translate into better treatments for rare as well as common diseases, such as thrombotic thrombocytopenic purpura and myocardial infarction.
